mesuximide mesuximide mesuximide (or methsuximide, methosuximide) is a succinimide anticonvulsant medication. it is sold as a racemate by pfizer under the tradenames petinutin (switzerland) and celontin (united states). the therapeutic efficacy of methosuximide is largely due to its pharmacologically active metabolite, n-desmethylmethosuximide, which has a longer half-life and attains much higher plasma levels than its parent. mesuximideclinical datatrade namescelontinahfs/drugs.comconsumer drug informationmedlineplusa682028routes ofadministrationby mouth (capsules)atc coden03ad03 (who) legal statuslegal status us: ℞-only pharmacokinetic datametabolismhepatic (demethylation and glucuronidation)metabolitesn-desmethylmethosuximideelimination half-life1.4–2.6 hours (mesuximide)28–38 hours (active metabolite)excretionurineidentifiers iupac name (rs)-1,3-dimethyl-3-phenyl-pyrrolidine-2,5-dione cas number77-41-8 ypubchem cid6476iuphar/bps7228drugbankdb05246 nchemspider6231 yunii0g76k8x6c0keggd00404 ychemblchembl697 ycomptox dashboard (epa)dtxsid5023293 echa infocard100.000.934 chemical and physical dataformulac12h13no2molar mass203.241 g·mol−13d model (jsmol)interactive imagechiralityracemic mixture smiles o=c2n(c(=o)cc2(c1ccccc1)c)c inchi inchi=1s/c12h13no2/c1-12(9-6-4-3-5-7-9)8-10(14)13(2)11(12)15/h3-7h,8h2,1-2h3 ykey:ajxpjjzhwixjcj-uhfffaoysa-n y ny (what is this?) (verify) medical use is indicated for the control of absence seizures that are refractory to other drugs.